Program
VVN461
A development code. Also written as “VVN461 Ophthalmic Solution 1.0%”, “VVN461 Ophthalmic Solution 0.5%” and “VVN461 Ophthalmic Solution 0.25%”.
Its studies are mostly in Uveitis, Anterior · Inflammation, led by VivaVision Biotech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| VivaVision Biotech | 41 open or running | phase 3since Aug 15, 2025 | Dec 1, 2023 | Dec 31, 2026phase 3 · NCT07136805 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 1, 2023First study: phase 2 study in InflammationFirst studyNCT06164743 · 91 enrolled · United States
- Nov 5, 2024Phase 2 study in Uveitis, AnteriorNCT06679153 · 89 enrolled · China
- Dec 3, 2024Phase 1 study in Healthy VolunteersNCT06906198 · 30 enrolled · China
- Aug 15, 2025Phase 3 study in Non-infectious Anterior UveitisNCT07136805 · 154 enrolled · China
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Non-infectious Anterior UveitisNCT07136805
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07136805Non-infectious Anterior Uveitis · China | 3 | Active, not recruiting | Dec 31, 2026 | 154 |
| NCT06906198Healthy Volunteers · China | 1 | Completed | May 10, 2023 | 30 |
| NCT06679153Uveitis, Anterior · China | 2 | Completed | Dec 29, 2024 | 89 |
| NCT06164743Inflammation · United States | 2 | Completed | May 15, 2024 | 91 |
How it is read
Names in the registry
- “VVN461 Ophthalmic Solution 1.0%”, 4 entries
- “VVN461 Ophthalmic Solution 0.5%”, 3 entries
- “VVN461 Ophthalmic Solution 0.25%”, 1 entry
Codes read as this program: VVN461.
Conditions, from the studies’ own filings
- Uveitis, Anterior, 2 studies
- Inflammation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.